Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Advances in radioprotection through the use of combined-agent regimens

Technical Report ·
OSTI ID:5998795
The most effective radioprotective agents exhibit toxicities that can limit their usefulness. It may be possible to use combinations of agents with different radioprotective mechanisms of action at less toxic doses, or to reduce the toxicity of the major protective compound by adding another agent. With regard to the latter possibility, improved radioprotection and reduced lethal toxicity of the phosphorothioate WR-2721 was observed when it was administered in combination with metals (selenium, zinc or copper). The known mechanisms of action of potential radioprotective agents and varying effects of different doses and times of administration in relation to radiation exposure must be considered when using combined-agent regimens. A number of receptor-mediated protectors and other biological compounds, including endotoxin, eicosanoids and cytokines, have at least an additive effect when administered before radiation exposure, whereas some immunomodulators have activity when administered with thiol protectors. Eicosanoids and other bioactive lipids must be administered before radiation, exposure, whereas some immunomodulators have activity when administered either before or after radiation exposure.
Research Organization:
Armed Forces Radiobiology Research Inst., Bethesda, MD (USA)
OSTI ID:
5998795
Report Number(s):
AD-A-227778/8/XAB; AFRRI-SR--90-24
Country of Publication:
United States
Language:
English